Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van Guselkumab bij pediatrische deelnemers met matig tot ernstig actieve ziekte van Crohn (MACARONI-23)

2 november 2026 bijgewerkt door: Janssen Research & Development, LLC

Een fase 3, multicenter, gerandomiseerd, platformonderzoek van p19-remming van de IL-23-route om werkzaamheid vast te stellen bij de ziekte van Crohn bij kinderen

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

Studie Overzicht

Toestand

Werving

Conditie

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Nedlands, Australië, 6009
        • Werving
        • Perth Children's Hospital
      • South Brisbane, Australië, 4101
        • Werving
        • Mater Hospital Brisbane
      • Westmead, Australië, 2145
        • Werving
        • The Children's Hospital at Westmead
      • Brussels, België, 1090
        • Werving
        • Universitair Ziekenhuis Brussel
      • Brussels, België, 1200
        • Werving
        • Cliniques Universitaires Saint Luc
      • Ghent, België, 9000
        • Werving
        • Universitair Ziekenhuis Gent
      • Leuven, België, 3000
        • Werving
        • UZ Leuven
      • Campinas, Brazilië, 13060-904
        • Werving
        • Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
      • Curitiba, Brazilië, 80250-060
        • Werving
        • Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
      • Goiânia, Brazilië, 74605-020
        • Werving
        • Universidade Federal de Goias - Hospital das Clinicas da UFG
      • Porto Alegre, Brazilië, 90035-074
        • Werving
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brazilië, 90035-007
        • Werving
        • Hospital De Clinicas De Porto Alegre
      • Vitória, Brazilië, 29040-091
        • Werving
        • Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
      • Votuporanga, Brazilië, 100000
        • Werving
        • INTEGRAL Pesquisa e Ensino
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 6R8
        • Werving
        • Iwk Health Centre
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Werving
        • London Health Sciences Centre Victoria Hospital
      • Toronto, Ontario, Canada, M5G 1X8
        • Werving
        • Hospital For Sick Children
      • Amiens, Frankrijk, 80054
        • Werving
        • CHU Amiens-Hopital Nord
      • Lille, Frankrijk, 59037
        • Werving
        • Hôpital Jeanne de FLANDRE, CHRU LILLE
      • Paris, Frankrijk, 75019
        • Werving
        • Hôpital Robert Debré
      • Paris, Frankrijk, 75015
        • Werving
        • Hôpital Necker - Enfants Malades
      • Beersheba, Israël, 84101
        • Werving
        • Soroka University Medical Center
      • Be’er Ya‘aqov, Israël, 70300
        • Werving
        • Shamir Medical Center Assaf Harofeh
      • Jerusalem, Israël, 9103102
        • Werving
        • Shaare Zedek Medical Center
      • Jerusalem, Israël, 9124001
        • Werving
        • Hadassah Medical Center
      • Petah Tikva, Israël, 4920235
        • Werving
        • Schneider Children's Medical Center
      • Rehovot, Israël, 761001
        • Werving
        • Kaplan Medical Center
      • Alessandria, Italië, 15121
        • Werving
        • A.O. Santi Antonio e Biagio e Cesare Arrigo
      • Bergamo, Italië, 24127
        • Werving
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
      • Bologna, Italië, 40124
        • Werving
        • Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
      • Florence, Italië, 50139
        • Werving
        • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
      • Milan, Italië, 20154
        • Werving
        • Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
      • Roma, Italië, 161
        • Werving
        • AOU Policlinico Umberto I
      • Hirosaki, Japan, 036-8563
        • Werving
        • Hirosaki University Hospital
      • Kagoshima, Japan, 890-8544
        • Werving
        • Kagoshima University Hospital
      • Kashiwa-shi, Japan, 277-0871
        • Werving
        • Tsujinaka Hospital Kashiwanoha
      • Kobe, Japan, 650 0017
        • Werving
        • Kobe University Hospital
      • Saga, Japan, 849-8501
        • Werving
        • Saga University Hospital
      • Sendai, Japan, 989-3126
        • Werving
        • Miyagi Childrens Hospital
      • Setagaya Ku, Japan, 157 8535
        • Werving
        • National Center for Child Health and Development
      • Tokyo, Japan, 113-8431
        • Werving
        • Juntendo University Hospital
      • Tsu, Japan, 514 8507
        • Werving
        • Mie University Hospital
      • Ube, Japan, 755-8505
        • Werving
        • Yamaguchi University Hospital
      • Yokohama, Japan, 232-0024
        • Werving
        • Yokohama City University Medical Center
      • Yokohama, Japan, 230-8765
        • Werving
        • Saiseikai Yokohamashi Tobu Hospital
      • Rotterdam, Nederland, 3015 GD
        • Werving
        • Erasmus Medisch Centrum
      • Nordbyhagen, Noorwegen, 1474
        • Werving
        • Akershus Universitetssykehus HF
      • Oslo, Noorwegen, 424
        • Werving
        • Oslo University Hospital
      • Tromsø, Noorwegen, 9038
        • Werving
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Noorwegen, 7030
        • Werving
        • St. Olavs Hospital
      • Vienna, Oostenrijk, 1090
        • Werving
        • AKH - Medizinische Universitat Wien
      • Rzeszów, Polen, 35-302
        • Werving
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polen, 04 501
        • Werving
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polen, 04 730
        • Werving
        • Instytut Pomnik Centrum Zdrowia
      • Braga, Portugal, 4710-243
        • Werving
        • Hospital de Braga
      • Lisbon, Portugal, 1649-035
        • Werving
        • Centro Hospitalar de Lisboa Norte Hospital Santa Maria
      • Porto, Portugal, 4200-319
        • Werving
        • Centro Hospitalar de Sao Joao E.P.E.
      • Córdoba, Spanje, 14004
        • Werving
        • Hosp Reina Sofia
      • Sabadell, Spanje, 8208
        • Werving
        • Corporacio Sanitari Parc Tauli
      • Valencia, Spanje, 46026
        • Werving
        • Hosp. Univ. I Politecni La Fe
      • Glasgow, Verenigd Koninkrijk, G51 4TF
        • Werving
        • Royal Hospital for Sick Children
      • London, Verenigd Koninkrijk, WC1N 3JH
        • Werving
        • Great Ormond Street Hospital
      • Manchester, Verenigd Koninkrijk, M13 9WL
        • Werving
        • Royal Manchester Children's Hospital
      • Manchester, Verenigd Koninkrijk, M13 9WL
        • Werving
        • Nowgen Centre, Research and Innovation
      • Oxford, Verenigd Koninkrijk, OX3 9DU
        • Werving
        • John Radcliffe Hospital
      • Sheffield, Verenigd Koninkrijk, S10 2TH
        • Werving
        • Sheffield Children's Hospital
    • California
      • Los Angeles, California, Verenigde Staten, 90048
        • Werving
        • Cedars Sinai Medical Center
    • Connecticut
      • Hartford, Connecticut, Verenigde Staten, 06106
        • Werving
        • Connecticut Children's Medical Center
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Werving
        • Emory University
      • Atlanta, Georgia, Verenigde Staten, 30342
        • Werving
        • Children's Center for Digestive Health Care
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202-5225
        • Werving
        • Riley Hospital for Children
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Werving
        • Boston Childrens Hospital
    • New Jersey
      • Morristown, New Jersey, Verenigde Staten, 07960
        • Werving
        • Goryeb Children's Hospital
    • New York
      • New York, New York, Verenigde Staten, 10029
        • Werving
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Verenigde Staten, 10032
        • Werving
        • Columbia University Medical Center
      • New York, New York, Verenigde Staten, 10021-5663
        • Werving
        • Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
    • Ohio
      • Dayton, Ohio, Verenigde Staten, 45404
        • Werving
        • The Children's Medical Center of Dayton
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Werving
        • Children's Hospital of Philadelphia
    • Texas
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Werving
        • Cook Childrens Medical Center
    • Vermont
      • Colchester, Vermont, Verenigde Staten, 05446
        • Werving
        • University of Vermont Medical Center
      • Busan, Zuid -Korea, 48108
        • Werving
        • Inje University Haeundae Paik Hospital
      • Daegu, Zuid -Korea, 41404
        • Werving
        • Kyungpook National University Chilgok Hospital
      • Seoul, Zuid -Korea, 03080
        • Werving
        • Seoul National University Hospital
      • Seoul, Zuid -Korea, 06351
        • Werving
        • Samsung Medical Center
      • Seoul, Zuid -Korea, 120-752
        • Werving
        • Severance Hospital Yonsei University Health System

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar tot 17 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
  • Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
  • Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
  • Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)

Exclusion Criteria:

  • Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
  • Participants must not have an abscess
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Open-label induction phase: Guselkumab Intravenously (IV)

Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Andere namen:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andere namen:
  • CNTO1959
  • TREMFYA
Experimenteel: Open-label induction phase: Guselkumab Subcutaneously (SC)

Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Andere namen:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andere namen:
  • CNTO1959
  • TREMFYA
Experimenteel: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andere namen:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andere namen:
  • CNTO1959
  • TREMFYA
Experimenteel: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andere namen:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andere namen:
  • CNTO1959
  • TREMFYA
Experimenteel: Open-label maintenance phase: Guselkumab SC

Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andere namen:
  • CNTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Andere namen:
  • CNTO1959
  • TREMFYA

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants with Clinical Remission at Week 52
Tijdsspanne: Week 52

Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Tijdsspanne: Week 52

Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline.

Week 52

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants with Clinical Response at Week 12
Tijdsspanne: Week 12

Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 12
Percentage of Participants with Clinical Response at Week 52
Tijdsspanne: Week 52

Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 52
Percentage of Participants with Clinical Remission at Week 12
Tijdsspanne: Week 12

Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 12
Percentage of Participants with Endoscopic Remission at Week 52
Tijdsspanne: Week 52

Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1.

Week 52
Percentage of Participants with Corticosteroid-free Remission at Week 52
Tijdsspanne: Week 52

Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52.

Week 52
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Tijdsspanne: Weeks 12, 24, and 52

Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52.

Weeks 12, 24, and 52
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Tijdsspanne: Week 12 and/or Week 52

Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline.

Week 12 and/or Week 52
Serum Concentration of Guselkumab During Induction Phase
Tijdsspanne: From Week 0 to Week 12

Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method.

From Week 0 to Week 12
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Tijdsspanne: At Weeks 16, 24, 36, 48 and 52

Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration.

At Weeks 16, 24, 36, 48 and 52
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52

Change from baseline in height at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52

Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52

Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52

Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Percentage of Participants with Clinical Remission
Tijdsspanne: Week 52

Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response
Tijdsspanne: Week 52

Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline.

Week 52
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Up to Week 64

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

Up to Week 64

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

13 maart 2024

Primaire voltooiing (Geschat)

27 oktober 2027

Studie voltooiing (Geschat)

14 augustus 2028

Studieregistratiedata

Eerst ingediend

20 juni 2023

Eerst ingediend dat voldeed aan de QC-criteria

20 juni 2023

Eerst geplaatst (Werkelijk)

28 juni 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • CR109212
  • 2021-006282-37 (EudraCT-nummer)
  • CNTO1959PBCRD3007 (Andere identificatie: Janssen Research & Development, LLC)
  • 2023-504735-41-00 (Register-ID: EUCT number)
  • 2023 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren